RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.

[1]  K. Sarin,et al.  Neurofibromatosis Type 1 and Risk of Skin Cancer. , 2022, JAMA dermatology.

[2]  R. Betensky,et al.  Genomic and transcriptomic analyses of NF1-mutant melanoma identify potential targeted approach for treatment. , 2022, The Journal of investigative dermatology.

[3]  Matthew R. Schwartz,et al.  Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study , 2022, Pigment cell & melanoma research.

[4]  L. Le,et al.  Neurofibromin and suppression of tumorigenesis: beyond the GAP , 2022, Oncogene.

[5]  J. Whisstock,et al.  The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1 , 2021, Nature Structural & Molecular Biology.

[6]  B. Rupp,et al.  The structure of neurofibromin isoform 2 reveals different functional states , 2021, Nature.

[7]  W. Wang,et al.  Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I. , 2021, The Journal of investigative dermatology.

[8]  L. Klesse,et al.  Insights into the Pathogenesis of NF1-Associated Neoplasms , 2021, JID innovations.

[9]  J. Brosseau,et al.  Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing , 2021, Acta neuropathologica communications.

[10]  F. McCormick,et al.  SPRED proteins and their roles in signal transduction, development, and malignancy , 2020, Genes & development.

[11]  D. Gutmann,et al.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. , 2020, The Journal of clinical investigation.

[12]  S. Naber,et al.  Decellularized extracellular matrix scaffolds identify full-length collagen VI as a driver of breast cancer cell invasion in obesity and metastasis , 2020, Science Advances.

[13]  S. Steinberg,et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.

[14]  R. Tiu,et al.  Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. , 2020, Clinical lung cancer.

[15]  D. Esposito,et al.  Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR , 2020, Cell reports.

[16]  S. Steinberg,et al.  Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. , 2020, Neuro-oncology.

[17]  Christopher B. Stanley,et al.  Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer , 2019, The Journal of Biological Chemistry.

[18]  Douglas C. Miller,et al.  Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass , 2019, Neuro-oncology advances.

[19]  C. Pratilas,et al.  Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling , 2019, bioRxiv.

[20]  I. Blanco,et al.  Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey , 2019, Orphanet Journal of Rare Diseases.

[21]  G. Sandusky,et al.  Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice , 2019, Molecular Cancer Therapeutics.

[22]  Pushpankur Ghoshal,et al.  Loss of GTPase activating protein neurofibromin stimulates paracrine cell communication via macropinocytosis , 2019, Redox biology.

[23]  G. Sandusky,et al.  Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. , 2019, Human molecular genetics.

[24]  Nancy F. Hansen,et al.  Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. , 2019, Neuro-oncology.

[25]  J. Brosseau,et al.  NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation , 2018, Nature Communications.

[26]  Robert J. Allaway,et al.  Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. , 2018, Cancer discovery.

[27]  P. Wolkenstein,et al.  Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells. , 2018, Cancer discovery.

[28]  A. Stemmer-Rachamimov,et al.  Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings , 2018, Human mutation.

[29]  Douglas C. Miller,et al.  Cutaneous neurofibromas , 2018, Neurology.

[30]  J. Brosseau,et al.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis , 2018, The Journal of clinical investigation.

[31]  B. Korf,et al.  Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.

[32]  K. Kosaki,et al.  Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1 , 2018, The Journal of dermatology.

[33]  E. Zackai,et al.  Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 , 2017, American journal of human genetics.

[34]  J. Teer,et al.  The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation , 2017, Scientific Reports.

[35]  Alexander V. Favorov,et al.  Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy , 2017, Clinical Cancer Research.

[36]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[37]  S. Peltonen,et al.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Kirkpatrick,et al.  The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[39]  D. Larouche,et al.  27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions , 2016, BioMed research international.

[40]  R. Mali,et al.  Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. , 2016, Human molecular genetics.

[41]  A. Halpern,et al.  NF1 Mutations Are Common in Desmoplastic Melanoma , 2015, The American journal of surgical pathology.

[42]  V. Riccardi.  Ketotifen suppression of NF1 neurofibroma growth over 30 years , 2015, American journal of medical genetics. Part A.

[43]  Alcino J. Silva,et al.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1 , 2015, Molecular Psychiatry.

[44]  N. Ratner,et al.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.

[45]  P. Wolkenstein,et al.  Treatment of Neurofibromas with a Carbon Dioxide Laser: A Retrospective Cross-Sectional Study of 106 Patients , 2015, Dermatology.

[46]  C. Liao,et al.  Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. , 2014, Cancer cell.

[47]  L. Qin,et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[48]  A. Guha,et al.  Neurofibromin interacts with the cytoplasmic Dynein Heavy Chain 1 in melanosomes of human melanocytes , 2013, FEBS letters.

[49]  G. Hutchins,et al.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. , 2012, The Lancet. Oncology.

[50]  N. Ratner,et al.  In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. , 2012, Cancer research.

[51]  L. Kluwe,et al.  Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1 , 2012, Orphanet Journal of Rare Diseases.

[52]  A. Burlingame,et al.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. , 2012, Genes & development.

[53]  D. Gutmann,et al.  Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner , 2012, Molecular and Cellular Neuroscience.

[54]  T. de Ravel,et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.

[55]  G. H. Vries,et al.  Aberrant cAMP Metabolism in NF1 Malignant Peripheral Nerve Sheath Tumor Cells , 2011, Neurochemical Research.

[56]  Jan Koster,et al.  NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.

[57]  N. Warrington,et al.  Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. , 2010, Cancer research.

[58]  Feng-Chun Yang,et al.  Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells , 2010, Current opinion in hematology.

[59]  Frank McCormick,et al.  The molecular pathology of cancer , 2010, Nature Reviews Clinical Oncology.

[60]  V. Golubovskaya,et al.  Neurofibromin physically interacts with the N‐terminal domain of focal adhesion kinase , 2009, Molecular carcinogenesis.

[61]  Kathleen R. Cho,et al.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. , 2008, Neoplasia.

[62]  J. Chernoff,et al.  Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. , 2008, Blood.

[63]  G. Hutchins,et al.  Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.

[64]  Alcino J. Silva,et al.  Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning , 2008, Cell.

[65]  H. Weinberg,et al.  Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[66]  A. Stemmer-Rachamimov,et al.  Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. , 2008, Cancer cell.

[67]  L. Parada,et al.  Tumor microenvironment and neurofibromatosis type I: connecting the GAPs , 2007, Oncogene.

[68]  M. Wilm,et al.  The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex. , 2007, Journal of molecular biology.

[69]  D. Ingram,et al.  K-ras Is Critical for Modulating Multiple c-kit-Mediated Cellular Functions in Wild-Type and Nf1+/− Mast Cells1 , 2007, The Journal of Immunology.

[70]  F. Speleman,et al.  Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non‐microdeletion patients , 2006, Genes, chromosomes & cancer.

[71]  G. Page,et al.  Impact of neurofibromatosis 1 on Quality of Life: A cross‐sectional study of 176 American cases , 2006, American journal of medical genetics. Part A.

[72]  L. Parada,et al.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. , 2006, Human molecular genetics.

[73]  I. D'Angelo,et al.  A novel bipartite phospholipid‐binding module in the neurofibromatosis type 1 protein , 2006, EMBO reports.

[74]  F. Mertens,et al.  Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma , 2005, International journal of cancer.

[75]  D. Gutmann,et al.  Neurofibromin Regulates Neural Stem Cell Proliferation, Survival, and Astroglial Differentiation In Vitro and In Vivo , 2005, The Journal of Neuroscience.

[76]  D. Gutmann,et al.  Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. , 2005, Cancer research.

[77]  D. Gutmann,et al.  Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. , 2003, Cancer research.

[78]  C. James,et al.  Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1 , 2003, Neurology.

[79]  D. Gutmann,et al.  The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes , 2003, The Journal of Neuroscience.

[80]  X. Estivill,et al.  Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients , 2003, Journal of medical genetics.

[81]  Y. Harada,et al.  Novel Mutations of Neurofibromatosis Type 1 Gene in Small Cell Lung Cancers , 2003, Surgery Today.

[82]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[83]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[84]  Alcino J. Silva,et al.  Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 , 2002, Nature.

[85]  Yu Cheng,et al.  Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. , 2001, Brain research. Developmental brain research.

[86]  M. Tatagiba,et al.  Loss of NF1 Alleles Distinguish Sporadic from NF1‐Associated Pilocytic Astrocytomas , 2001, Journal of neuropathology and experimental neurology.

[87]  David A. Williams,et al.  Hyperactivation of P21ras and the Hematopoietic-Specific Rho Gtpase, Rac2, Cooperate to Alter the Proliferation of Neurofibromin-Deficient Mast Cells in Vivo and in Vitro , 2001, The Journal of experimental medicine.

[88]  R. Gutzmer,et al.  Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma , 2000, Human Genetics.

[89]  David A. Williams,et al.  Genetic and Biochemical Evidence That Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo , 2000, The Journal of experimental medicine.

[90]  K. Shannon,et al.  Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, American journal of medical genetics.

[91]  R. Berkowitz,et al.  Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors , 1999, Oncogene.

[92]  K. Shannon,et al.  Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. , 1998, Blood.

[93]  X. Estivill,et al.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.

[94]  D. Cooper,et al.  Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene , 1996, Human Genetics.

[95]  D. Viskochil,et al.  Identification of NF1 mutations in both alleles of a dermal neurofibroma , 1996, Nature Genetics.

[96]  P S Harper,et al.  Molecular genetics of neurofibromatosis type 1 (NF1). , 1996, Journal of medical genetics.

[97]  S. Colman,et al.  Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene , 1995, Nature Genetics.

[98]  D. Gutmann,et al.  Loss of neurofibromatosis type I (NFI) gene expression in pheochromocytomas from patients without NFI , 1994, Genes, chromosomes & cancer.

[99]  C. Der,et al.  The Ras signal transduction pathway , 1994, Cancer and Metastasis Reviews.

[100]  A. Look,et al.  Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Daston,et al.  Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development , 1992, Developmental dynamics : an official publication of the American Association of Anatomists.

[102]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[103]  P. O'Connell,et al.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.

[104]  S. Huson,et al.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. , 1989, Journal of medical genetics.

[105]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[106]  P. Rowley,et al.  Molecular genetic analysis of tumors in von recklinghausen neurofibromatosis: Loss of heterozygosity for chromosome 17 , 1989, Genes, chromosomes & cancer.

[107]  H. Larjava,et al.  Collagens in Neurofibromas and Neurofibroma Cell Cultures , 1986, Annals of the New York Academy of Sciences.

[108]  M. Skolnick,et al.  The Genetic Aspects of Neurofibromatosis a , 1986, Annals of the New York Academy of Sciences.

[109]  A. Leplège,et al.  Visibility of neurofibromatosis 1 and psychiatric morbidity. , 2003, Archives of dermatology.

[110]  M. Barbacid.  ras genes. , 1987, Annual review of biochemistry.